Collagen Stimulators: PLLA, PDLLA, CaHA and PCL — Composition and Differences

We explain what collagen biostimulators are made of, how they work, and how they differ from fillers and skin boosters. In this article, we review four groups of injectable materials and widely used products based on them: Sculptra with poly-L-lactic acid (PLLA), AestheFill and Juvelook with poly-D,L-lactic acid (PDLLA), Radiesse with calcium hydroxylapatite (CaHA), and Ellansé with polycaprolactone (PCL).

What collagen stimulators are

The term “collagen stimulator” is a general name for various injectable materials whose action is linked to a gradual tissue response and the formation of new collagen. It is not a single substance: this group includes, among others, products based on poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), calcium hydroxylapatite (CaHA), and polycaprolactone (PCL). Composition, physical structure, mechanism of action, and indications depend on the specific product.

After injection, the material interacts with the tissues around the injection site. Depending on the material, the local response may involve immune-system cells, including macrophages, as well as fibroblasts — the cells that synthesize collagen and other components of the extracellular matrix. As tissues remodel, a new collagen matrix may form, while the material itself gradually changes within the tissue environment.

The sequence and intensity of these processes depend on the material. Therefore, the term “collagen stimulator” describes a shared principle of action, but by itself it does not define the mechanism, speed, or clinical outcome. Next, we will look at how the main materials and formulas differ.

PLLA: Sculptra

PLLA is poly-L-lactic acid, a biodegradable synthetic polymer. Sculptra contains PLLA microparticles, carboxymethylcellulose, and mannitol. Before the procedure, the powder is reconstituted with sterile water to form a suspension. Early swelling is partly related to the fluid used to reconstitute the product and to the tissue response to the injection. As it subsides, this initial volume decreases. Subsequent changes build gradually as tissues respond to the PLLA particles and the collagen matrix remodels.

This process was studied in a placebo-controlled study with histological assessment of PLLA. Participants received three treatments at four-week intervals; 18 weeks after the last treatment, the researchers recorded changes in skin quality, tissue remodeling, and the formation of new blood vessels in tissue samples.

For the correction of fine lines on the cheeks, the FDA materials on Sculptra describe a clinical study in which patients received up to four injection sessions for the best result; the effect could last up to 24 months.

CaHA: Radiesse

CaHA refers to synthetic microspheres of calcium hydroxylapatite, a material with a mineral structure. In Radiesse, the microspheres are suspended in a carboxymethylcellulose gel: approximately 30% of the formula is CaHA and 70% is the carrier. The gel provides immediate support and volume, while the microspheres trigger a subsequent tissue response. Studies have observed changes in collagen and elastin after CaHA. For example, in a controlled histomorphological study comparing CaHA with a hyaluronic acid filler, a higher level of type III collagen was found after four months on the side treated with CaHA.

The properties of the mixture depend on dilution: in a formula for volume correction, mechanical tissue support is more pronounced, while a diluted product can be distributed over a larger area with a smaller immediate volumizing effect. In a pilot study of diluted CaHA for the neck and décolleté involving 20 people, changes were assessed up to month seven after two treatments. Biopsy samples showed increased markers of type I and type III collagen, elastin, and blood vessel formation; measurements also showed improved elasticity and dermal thickness.

In the United States, the FDA approved Radiesse diluted 1:2 with saline on March 31, 2026, for the correction of décolleté wrinkles in patients aged 22 and older. For a comparison of the features of CaHA and PLLA, including Radiesse and Sculptra, see the article “CaHA or PLLA: How to Choose a Collagen Biostimulator”.

PCL: Ellansé

PCL is polycaprolactone, a biodegradable polyester. It is a separate type of polymer, different from the lactic acid polymers PLLA and PDLLA. In Ellansé, PCL microspheres are suspended in a carboxymethylcellulose gel. The gel creates early volume, while the PCL particles support subsequent tissue remodeling. The duration of the effect is related to the properties of the specific version of the product: the manufacturer states a range of 18 months to three years for the line, with the upper estimates based on extrapolation of clinical data.

In a 24-month randomized study of two PCL formulas, Ellansé-S and Ellansé-M were compared for the correction of nasolabial folds in 40 participants. The procedure included two injections one month apart. After 12 months, improvement was maintained in both groups, and after 24 months, PCL-2 demonstrated a longer-lasting effect based on wrinkle severity and global aesthetic improvement scores.

PDLLA: AestheFill, Juvelook, and other formulas

PDLLA is poly-D,L-lactic acid. Unlike PLLA, the PDLLA polymer chain is formed by D- and L-forms of lactic acid. Both materials are biodegradable, but they are different polymers with distinct particle structures and properties. Therefore, the name PDLLA alone does not describe the full formula or the early effect of the product.

AestheFill contains PDLLA microspheres and carboxymethylcellulose; the product is reconstituted before injection. In the Juvelook line, PDLLA is combined with non-crosslinked hyaluronic acid. Hyaluronic acid contributes to early hydration and filling, while the tissue action of PDLLA develops gradually. In clinical publications, the standard version of Juvelook has been described as a formula containing 42.5 mg of PDLLA and 7.5 mg of hyaluronic acid, while Juvelook Volume has been described as a formula containing 170 mg and 30 mg, respectively. Thus, the versions differ in the amount of components, even when their ratio in the described formulas is the same. The standard Juvelook formula is used in procedures aimed at fine lines and skin quality, while Juvelook Volume is positioned for more pronounced volumetric filling. The choice depends not only on the total amount of PDLLA, but also on particle characteristics, injection technique, and the specific indication.

Different PDLLA formulas have been studied separately. In a randomized study of AestheFill, the product was compared with a hyaluronic acid filler for nasolabial fold correction. Another study, a randomized trial comparing Juvelook Volume with Sculptra, included 33 people: a PDLLA formula with hyaluronic acid was injected on one side of the face, and PLLA on the other. After three treatments at four-week intervals, both products improved nasolabial fold scores; Juvelook Volume was confirmed to be non-inferior to Sculptra during 24 weeks of follow-up.

How collagen biostimulators differ from fillers and skin boosters

These names describe different characteristics of a product or procedure: “filler” refers to the role of the material, “collagen biostimulator” to its tissue action, and “skin booster” to the direction or goal of the procedure. Therefore, these concepts can overlap.

Sculptra shows how these concepts overlap: in FDA materials, it is described as a gel implant or dermal filler, while in aesthetic practice the product is also classified as a collagen biostimulator because it contains PLLA.

A 2026 review of skin boosters covers various materials and methods of use, including injectable and device-based approaches. This is a broad concept, so the name skin booster alone does not indicate the product’s composition or the expected tissue action. PN and PDRN may also be mentioned among materials for skin booster procedures, but they are DNA-derived substances, not types of PLLA, PDLLA, CaHA, or PCL. Read more about them in the article “Polynucleotides and PDRN in Aesthetic Medicine: Where Is the Evidence and Where Is the Marketing?”.

For the differences between hyaluronic acid fillers, biorevitalization, and skin boosters, read the article Cosmetics or Hyaluronic Acid Injections: What to Choose and for Which Goals.

What to clarify before the procedure

Before an injection, it is worth knowing the exact name of the product, not just the words “biostimulator,” “collagen stimulator,” or “skin booster.” Ask the doctor to name the main material, the full product version, and explain how its composition relates to the planned effect.

Risks and contraindications

After an injection, pain or tenderness, redness, swelling, and bruising may occur. Less commonly, nodules or lumps, an inflammatory reaction, or infection may develop; some reactions appear with a delay. The most serious rare complication of injectable administration is material entering a blood vessel and disrupting blood flow. This can lead to tissue necrosis, visual impairment up to blindness, or stroke. FDA: risks of injectable dermal fillers.

Unusual severe pain, blanching or a sudden change in skin color near the injection site, worsening vision, weakness, numbness, or speech disturbance during or shortly after the procedure require urgent medical attention.

The list of contraindications depends on the specific product. Active inflammation or infection in the treatment area is a reason to postpone the procedure; a known allergy to product components is a contraindication. For example, the FDA labeling for Sculptra also lists a history of severe allergic reactions and a tendency to form keloid or hypertrophic scars. The safety of Sculptra during pregnancy and breastfeeding has not been studied. Tell your doctor about pregnancy or lactation, blood-clotting disorders, and any medications that affect clotting or immunity. Final restrictions should be checked against the instructions for the specific formula selected.

• Which exact product and material will be used? Clarify the brand, model, and additional components, including whether hyaluronic acid is present.
• For which area and indication is it being recommended? Check whether this matches the instructions for the specific product and its registration status in the country where the procedure is performed.
• When will the result be assessed? For some formulas, early volume from the gel carrier is important; for others, the gradual tissue response matters more. These timelines cannot be determined from the general name of the material alone.
• What correction options are available if the result is undesirable or a complication occurs? Hyaluronidase is suitable for hyaluronic acid (HA) fillers, but it is not a universal remedy for PLLA, PDLLA, CaHA, or PCL.

If you need a broader overview of how to choose procedures and assess injection safety, see the article “Aesthetic Medicine: How to Navigate Methods, Safety, and Realistic Expectations”.

Conclusion

PLLA, PDLLA, CaHA, and PCL differ in composition, structure, and interaction with tissues. The term “filler” describes the role of the product, “collagen biostimulator” describes its tissue action, and “skin booster” describes the direction of the procedure. For comparison, the full product name, its composition, indications for a specific area, the expected timeline for visible results, and the risk profile all matter. The evidence base varies across formulas, so there is no universal ranking of products: the choice depends on the clinical goal and the properties of the specific product.

Sources

1. U.S. Food and Drug Administration. Sculptra - P030050/S039.
2. U.S. Food and Drug Administration. FDA-Approved Dermal Fillers.
3. U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers): Risks and Patient Information.
4. U.S. Food and Drug Administration. Sculptra: Patient Labeling, P030050/S039.
5. U.S. Food and Drug Administration. Radiesse, Supplement S162: Approval for Diluted Use in Décolleté Wrinkles. 2026.
6. Merz Aesthetics. RADIESSE: Composition and Indications.
7. ELLANSÉ. Frequently Asked Questions: Composition and Expected Duration.
8. REGEN Biotech. AestheFill Product Information.
9. VAIM. JUVELOOK Product Composition.
10. Magacho-Vieira FN, et al. Consensus recommendations for the reconstitution and aesthetic use of poly-D,L-lactic acid microspheres. Clinical, Cosmetic and Investigational Dermatology. 2024;17:2755-2765. doi:10.2147/CCID.S497691.
11. Ting W, et al. A randomized, evaluator-blinded, multicenter study to compare injectable poly-D,L-lactic acid vs hyaluronic acid for nasolabial fold augmentation. Aesthetic Surgery Journal. 2024;44(12):NP898-NP905. doi:10.1093/asj/sjae180.
12. Smith L, et al. Biostimulants in aesthetic medicine: a systematic review and meta-analysis of efficacy, safety, and patient satisfaction. Aesthetic Surgery Journal. 2025;45(12):1278-1284. doi:10.1093/asj/sjaf142.
13. Ferreira ACM, et al. Efficacy, durability, and safety of collagen biostimulators based on PLLA and CaHA in the face: a systematic review. Aesthetic Plastic Surgery. 2026;50(3):1291-1300. doi:10.1007/s00266-025-05412-8.
14. Yi KH, et al. Skin boosters: 2026 updated. Journal of Cosmetic Dermatology. 2026;25(6):e70875. doi:10.1111/jocd.70875.
15. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatologic Surgery. 2013;39(3 Pt 1):457–463. doi:10.1111/dsu.12054.
16. U.S. Food and Drug Administration. Radiesse Injectable Implant, P050052/S162. Approval decision: March 31, 2026.
17. A Split Face Study Comparing the Effect of a PDLLA Based Product and PLLA on the Nasolabial Fold (NLF).